Skip to main content

UK Based T Cell Therapy Company Selects Maryland for New US Commercial Manufacturing Facility · BioBuzz

By September 24, 2018News
autolus-logo

autolus-logo

Autolus Therapeutics is a promising clinical-stage biotech that is a leader in T-cell programming and manufacturing technology. They have seen rapid growth since launching in 2014, and recently executed a successful US IPO in June that raised $160.4M at a $17 share price and landed them on the Nasdaq (AUTL).

{iframe}https://biobuzz.io/t-cell-therapy-company-selects-maryland-for-new-us-commercial-manufacturing-facility/{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.